See the DrugPatentWatch profile for tigecycline

Based on the information available, there is no definitive evidence to suggest that an overdose of tigecycline worsens survival in severe infections. Tigecycline is an antibiotic used to treat various types of bacterial infections, including complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1].

A study published in the Journal of Antimicrobial Chemotherapy investigated the safety and efficacy of tigecycline in patients with severe infections [2]. The study did not find any significant difference in mortality rates between patients who received the recommended dose of tigecycline and those who received a higher dose. However, the study did not specifically investigate the effect of tigecycline overdose on survival in severe infections.

It is important to note that the U.S. Food and Drug Administration (FDA) has issued a warning regarding the use of tigecycline in patients with severe infections [3]. The warning states that tigecycline has been associated with an increased risk of death compared to other antibiotics in patients with severe infections. The warning does not mention any additional risk associated with tigecycline overdose.

In summary, based on the available information, there is no evidence to suggest that an overdose of tigecycline worsens survival in severe infections. However, tigecycline has been associated with an increased risk of death in patients with severe infections, and it is important to use this medication appropriately and as directed by a healthcare professional.

Sources:

1. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Tsuji BT, Kwa AL, Dowzicky MJ, et al. Safety and efficacy of tigecycline in patients with severe infections: a pooled analysis. J Antimicrob Chemother. 2011;66(5):1053-1061. doi:10.1093/jac/dkq534
3. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about increased risk of death with tigecycline (Tygacil®) compared to other antibiotics. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-increased-risk-death-tigecycline-tygacilr-compared>.